Results 1 to 10 of about 3,137 (197)

Incidence of loiasis clinical manifestations in a rural area of the Republic of Congo: Results from a longitudinal prospective study (the MorLo project). [PDF]

PLoS Neglected Tropical Diseases
BackgroundLoiasis is endemic in Central Africa. Despite evidence of clinical complications and increased mortality, it remains excluded from the list of neglected tropical diseases. The main manifestations are Calabar swellings (CS), Eyeworm (EW) and non-
Jérémy T Campillo, Biam-Miveck Pakat-Pambou, Bachiratou Sahm, Sébastien D S Pion, Marlhand C Hemilembolo, Elodie Lebredonchel, Michel Boussinesq, François Missamou, Cédric B Chesnais   +8 more
doaj   +3 more sources

The economic burden of loiasis: A comprehensive cost-of-illness analysis of regionally representative, individual-level data from rural Gabon. [PDF]

PLoS ONE
Loiasis is a vector-borne filarial infection endemic to parts of sub-Saharan Africa. It disproportionally affects economically disadvantaged communities in rural, forested regions.
Cédric Isaac Mbavu, Kerstin Perlik, Tom Stargardt, Selidji Todagbe Agnandji, Olouyomi Scherif Adegnika, Rella Zoleko-Manego, Michael Ramharter, Jan Priebe   +7 more
doaj   +3 more sources

There Is No Association Between Loiasis and Malaria: Findings from a Secondary Analysis of a Cross-Sectional Survey in Rural Gabon [PDF]

Tropical Medicine and Infectious Disease
Loiasis exists in regions where malaria is highly endemic, yet few studies have investigated their association as concomitant infectious diseases. Secondary data analysis from a cross-sectional survey conducted in Gabon (2015–2016) was performed to ...
Jacob Werner, Rella Zoleko-Manego, Ghyslain Mombo-Ngoma, Michael Ramharter, Johannes Mischlinger   +4 more
doaj   +3 more sources

Treatment of loiasis: a review of clinical management recommendations [PDF]

Infectious Diseases of Poverty
Background Loiasis affects more than 20 million residents of endemic regions in Central and West Africa causing chronic and often lifelong disease. Antifilarial treatment options for loiasis include diethylcarbamazine, ivermectin, and albendazole.
Dorothea Ekoka Mbassi, Rike Dreeßen, Rella Zoleko Manego, Saskia Dede Davi, Tamara Nordmann, Johannes Mischlinger, Michael Ramharter   +6 more
doaj   +3 more sources

Evaluation of knowledge, attitude and practices towards loiasis in the rural community of Sindara, in central African Gabon. [PDF]

PLoS Neglected Tropical Diseases
BackgroundMore than 20 million people are infected with L. loa, and around 40 million live in high or intermediate-risk areas in West- and Central Africa.
Teite Rebecca Hildebrandt, Saskia Dede Davi, Anita Lumeka Kabwende, Lilian Rene Endamne, Esther Mehmel, Maximilian Rakotonirinalalao, Ayodele Alabi, Rella Zoleko Manego, Peter G Kremsner, Bertrand Lell, Ayôla Akim Adegnika, Ghyslain Mombo-Ngoma, Johannes Mischlinger, Selidji Todagbe Agnandji, Michael Ramharter   +14 more
doaj   +3 more sources

Reported healthcare-seeking of loiasis patients and estimation of the associated monetary burden in Gabon: Data from a cross-sectional survey. [PDF]

PLoS Neglected Tropical Diseases
BackgroundLoiasis is a disease of relevance in endemic populations and there has been advocacy for its inclusion on the World Health Organization's neglected tropical diseases list.
Luzia Veletzky, Veronika Schlicker, Jennifer Hergeth, Daniel R Stelzl, Rella Zoleko Manego, Ghyslain Mombo-Ngoma, Kirsten Alexandra Eberhardt, Matthew B B McCall, Ayôla A Adegnika, Bertrand Lell, Benjamin Mordmüller, Scherif Adegnika, Michael Ramharter, Christine Budke   +13 more
doaj   +3 more sources

Ocular loiasis in a pediatric patient: description of a case without microfilaremia [PDF]

BMC Ophthalmology
Background Loiasis is a parasitic disease caused by the filarial nematode Loa loa. Case presentation This report describes loiasis in a 6-year-old child presented to a public hospital in Yaoundé, Cameroon, with an immobile worm located beneath the ...
André Domche, Arlette Nomo, Raissa Dongmo Yemele, Hugues C. Nana Djeunga   +3 more
doaj   +3 more sources

Safety and efficacy of 3- and 5-day regimens of levamisole in loiasis: a randomized, placebo-controlled, double-blind clinical trial [PDF]

Nature Communications
Individuals with high Loa loa microfilarial densities (MFD) risk serious adverse events (SAEs) following ivermectin treatment. A single dose of levamisole (LEV) induces a temporary, progressive MFD decrease.
Cédric B. Chesnais, Marlhand C. Hemilembolo, Bachiratou A. Sahm, Florentin Toutin, Ericson Djeutassong, Nadia Nga-Elomo, Benjamin Cuer, Mas A. Ntsiba-N’Goulou, Miveck Pakat, Sébastien D. S. Pion, François Missamou, Michel Boussinesq, Jérémy T. Campillo   +12 more
doaj   +3 more sources

Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: A systematic review. [PDF]

PLoS Neglected Tropical Diseases
BackgroundThe design and analysis of randomized clinical trials (RCTs) in filarial diseases such as onchocerciasis, loiasis, and mansonellosis pose unique statistical challenges, including skewed endpoints and limited sample sizes. This systematic review
Fabrice Lotola Mougeni, Marta Bofill Roig, Marc P Hübner, Ute Klarmann-Schulz, Benjamin Lenz, Sabine Specht, Martin Posch, Sonja Zehetmayer   +7 more
doaj   +3 more sources

A novel antigen biomarker for detection of high-level of Loa loa microfilaremia. [PDF]

PLoS Neglected Tropical Diseases
BackgroundLoiasis is a disease caused by the nematode Loa loa. Serious adverse events sometimes occur in people with heavy L. loa microfilaremia after ivermectin treatment. In regions of Central Africa where loiasis is endemic, this significantly impedes
Sarah E Greene, Yuefang Huang, Kerstin Fischer, Bruce A Rosa, John Martin, Makedonka Mitreva, Devyn Yates, Samuel Wanji, Joseph Kamgno, Philip J Budge, Gary J Weil, Peter U Fischer   +11 more
doaj   +2 more sources